新光药业(300519.SZ)：2025年三季报净利润为4533.62万元

Financial Performance - The company's total operating revenue is 206 million yuan, a decrease of 10.59 million yuan compared to the same reporting period last year, representing a year-on-year decline of 4.90% [1] - The net profit attributable to shareholders is 45.3362 million yuan, with net cash inflow from operating activities amounting to 50.5881 million yuan [1] Financial Ratios - The latest debt-to-asset ratio is 7.33% [3] - The latest gross profit margin is 39.12% [3] - The latest return on equity (ROE) is 5.48% [3] Earnings and Turnover - The diluted earnings per share are 0.28 yuan [4] - The latest total asset turnover ratio is 0.23 times, a decrease of 0.01 times compared to the same period last year, reflecting a year-on-year decline of 3.84% [4] - The latest inventory turnover ratio is 1.93 times, a decrease of 0.18 times compared to the same period last year, indicating a year-on-year decline of 8.54% [4] Shareholder Information - The number of shareholders is 15,600, with the top ten shareholders holding a total of 91.7539 million shares, accounting for 57.35% of the total share capital [4] - The largest shareholder is Wang Yuejun, holding 38.25% of the shares [4]